Biotech startup Zymergen nabs $130 million from Softbank
Bay Area startup Zymergen, which creates all sorts of materials from genetically altered microbes, recently raised $130 million in Series B funding. Softbank led the round for Zymergen and was joined by previous investors DCVC, True Ventures, AME Cloud Ventures, DFJ, Innovation Endeavors, Obvious Ventures, and Two Sigma.